Putting Chronic Migraine on the Map:
The Transforming Landscape of Diagnosis,
Pathophysiology, and Novel Therapeutic Options


Please review the CE/CME information below, and click “continue” to view the activity.


Intended Audience

This activity is intended for neurologists, neuroscientists, and other headache specialists.


Statement of Need

Chronic migraine (CM) is a highly disabling neurologic disorder, with heterogeneous characteristics resulting in a range of symptom profiles, burden, and disability, that remains largely underdiagnosed and undertreated. Affecting nearly 2% of the general population, CM is one of the most disabling of the primary headache disorders, imposing considerable economic burden while interfering with social, occupational, and educational functioning; it remains an enormous challenge in neurologic and headache practices.

Though there are no currently US Food and Drug Administration–approved treatments for CM prophylaxis, treatment of CM has evolved into a multifaceted approach, including lifestyle modification, trigger management, behavioral therapy, pharmacologic therapy, education, support, management of expectations, and close follow-up. Topiramate, divalproex, and onabotulinumtoxinA have been evaluated as prophylactic treatment of CM in randomized, double-blind, placebo-controlled or active comparator-controlled trials.

This activity will review the pathophysiology, diagnosis, clinical practice guidelines, and optimal management of CM. In addition, faculty will discuss current clinical trials on medication overuse and CM prophylaxis. Participants will have the opportunity to pose questions to the faculty panelists for an interactive and open discussion.


Educational Objectives

At the conclusion of this activity, participants should be better able to:

Accreditation and Certification
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and CogniMed Inc. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by mail following activity participation and upon completion and electronic submission of the posttest and evaluation to CogniMed Inc. A link to the evaluation is provided within the activity. Please allow 4 to 6 weeks for the delivery of your statement.


Chairperson

Sheena K. Aurora, MD
Director, Swedish Headache Center
Swedish Pain and Headache Center
Seattle, Washington


Faculty

Dawn C. Buse, PhD
Assistant Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva
   University
Assistant Professor, Clinical Health Psychology
   Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva
   University
Director of Behavioral Medicine
Montefiore Headache Center
New York, New York
David W. Dodick, MD, FRCPC
Professor of Neurology
Mayo Clinic College of Medicine
Scottsdale, Arizona

Disclosures
Sheena K. Aurora, MD, has received grants and research support from Advanced Bionics Corporation; Alexza Pharmaceuticals, Inc.; Allergan, Inc.; GlaxoSmithKline; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Neuralieve Inc.; and Ortho-McNeil Pharmaceutical, Inc.; and has served as a consultant for Allergan, Inc.; GlaxoSmithKline; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Neuralieve Inc.; Ortho-McNeil Pharmaceutical, Inc.; and Pfizer Inc. She has received honoraria from GlaxoSmithKline; Merck & Co., Inc.; Ortho-McNeil Pharmaceutical, Inc.; and Pfizer Inc.

Dawn C. Buse, PhD, is a consultant for Allergan, Inc.; Endo Pharmaceuticals Inc.; Iroko Pharmaceuticals; and MAP Pharmaceuticals, Inc.

David W. Dodick, MD, FRCPC, receives research support from Advanced Neuromodulation Systems, Inc.; Medtronic, Inc.; and St. Jude Medical, Inc. He is a consultant for Alexza Pharmaceuticals, Inc.; Allergan, Inc.; Boston Scientific Corporation; Bristol-Myers Squibb Company; CogniMed Inc.; Coherex Medical, Inc.; Eli Lilly and Company; Impax; Kowa Pharmaceuticals America, Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Miller Medical; Minster Pharmaceuticals; Neuralieve Inc.; NeurAxon; Novartis; NuPathe Inc.; Pfizer Inc; SAGE Publications; and Zogenix, Inc.

All staff at the Annenberg Center and CogniMed Inc. have nothing to disclose.

This program may contain discussion of investigational uses of pharmacologic and nonpharmacologic therapies. Individual clinical judgments should be used in all patient care decisions.

This activity is supported by an independent educational grant provided by Allergan, Inc.

This activity is an enduring material and consists of a Web posting. Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 1.5 hours.

This activity was originally released November 30, 2010, and is available for credit through November 30, 2011.